Allergy Thera. Regulatory News (AGY)

2 May 2012

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Company")

Appointment of a Non-Executive Director

Allergy Therapeutics (AIM: AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, is pleased to announce that it has appointed with immediate effect Dr. Thomas Lander, as a Non-Executive Director with European regulatory experience.

Dr Thomas Lander will replace Dr Virinder Nohria, and will be responsible for overseeing the Company's research and development activities. Dr Nohria retires from the Board on 30 June 2012, as Non-Executive Director.

Thomas has more than 25 years experience in the biopharmaceutical industry. He has held a number of senior management positions with international pharmaceutical companies including Boehringer Ingelheim, NovoNordisk and Bristol-Myers Squibb. Thomas was European Medical Director of GlaxoWellcome until the merger that resulted in GlaxoSmithKline before he became Global Head of Clinical Development and Chief Medical Officer of Merck KGaA (now MerckSerono). He was appointed Managing Director of CureVac GmbH in 2006. Since 2009 he has been working as an independent strategic consultant.

Peter Jensen Chairman of Allergy Therapeutics commented:

"We are delighted to welcome Thomas to the Board. He brings extensive industry and board experience, which will be invaluable to the Company as it continues to execute its global R&D strategy."

Additional information regarding Thomas Lander

Thomas Lander aged 59 has the following appointments as a director or partner within the past 5 years:

There are no further disclosures required under Schedule 2 paragraph (g) of the AIM rules.

For further information

Notes to editors

About Allergy Therapeutics

Allergy Therapeutics is a specialty pharmaceutical company focused on allergy vaccination. It has a growing business achieving sales in the prior financial year of £42 million mainly in Europe through its own sales and marketing infrastructure and further afield through distributors. The Company is expanding its infrastructure into the Emerging Markets.